Biological therapies for eosinophilic asthma

References

• Holgate ST, Arshad HS, Roberts GC, et al. A new look at the pathogenesis of asthma. Clin Sci. 2010;118:439–450.
   Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy. 2004;59(5):469–478.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristics, and self-management education: united States, 2001–2009. MMWR Morb Mortal Wkly Rep. 2001;60(17):547–552.
   Google Scholar
• Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the most important questions? J Allergy Clin Immunol. 2007;119(6):1337–1348.
   PubMed Web of Science ®Google Scholar
• Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61–67.
   PubMed Web of Science ®Google Scholar
• Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107–1119.
   PubMed Web of Science ®Google Scholar
• Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps towards personalized care. J Allergy Clin Immunol. 2015;135(2):299–310.
   PubMed Web of Science ®Google Scholar
• Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Reslizumab in the treatment of severe eosinophilic asthma: an update. Immunotherapy. 2018 Mar 20.
   PubMed Web of Science ®Google Scholar
• Nair P. What is an “eosinophilic phenotype” of asthma? J Allergy Clin Immunol. 2013;132(1):81–83.
   PubMed Web of Science ®Google Scholar
• Poon AH, Eidelman DH, Martin JG, et al. Pathogenesis of severe asthma. Clin Exp Allergy. 2012;42:625–637.
   PubMed Web of Science ®Google Scholar
• Louis R, Lau LC, Bron AO, et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000 Jan;161(1):9–16.
   PubMed Web of Science ®Google Scholar
• Foster PS, Hogan SP, Ramsay AJ, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996 Jan 1;183(1):195–201.
   PubMed Web of Science ®Google Scholar
• Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014;20:87–94.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention, 2016. Available from: www.ginasthma.org. 16 January 2018.
   Google Scholar
• Garcia G, Taillé C, Laveneziana P, et al. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev. 2013 Sep 1;22(129):251–257.
   PubMedGoogle Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250–257.
   PubMed Web of Science ®Google Scholar
• Giannetti MP, Cardet JC. Interleukin-5 antagonists usher in a new generation of asthma therapy. Curr Allergy Asthma Rep. 2016 Nov;16(11):80.
   PubMed Web of Science ®Google Scholar
• Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000 Dec 23–30; 356(9248):2144–2148.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al., International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ J. 2014 Dec 4;7(1):32.
   PubMedGoogle Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003 Jan 15;167(2):199–204. Epub 2002 Oct 17.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar 5;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 Mar 5;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18; 380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al., SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al., MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016 Jul;4(7):549–556. Epub 2016 May 10.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014 Mar;133(3):921–923.
   PubMed Web of Science ®Google Scholar
• Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1655–1659.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Res-5-0010 Study Group Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125–1132.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May;3(5):355–366.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016 Oct;150(4):789–798.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016 Oct;150(4):799–810.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al., International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Sehmi R, Smith SG, Kjarsgaard M, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy. 2016 Jun;46(6):793–802.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin sImmunol. 2013 Nov;132(5):1086–1096.e5.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014 Nov;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al., SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115–2127.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Bleecker ER, Nair P, et al., CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128–2141.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al., ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017 Jun 22;376(25):2448–2458.
   PubMed Web of Science ®Google Scholar
• Nucala (Mepolizumab) [package insert]. Philadelphia, PA: GSK; 2017.
   Google Scholar
• Cinqair (Reslizumab) [package insert]. Frazer, PA: TevaRespi; 2017.
   Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.  J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1572–1581.e3.
   Google Scholar
• Cazzola M, Matera MG, Levi-Schaffer F, et al. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin Drug Saf. 2018 Apr;17(4):429–435.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018 Jan 1;197(1):38–46.
   PubMed Web of Science ®Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157–162.
   PubMed Web of Science ®Google Scholar
• Cheng YX, Foster B, Holland SM, et al. CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI. Clin Exp Allergy. 2006 Nov;36(11):1436–1445.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003 Dec;112(6):1147–1154. PubMed PMID: 14657874.
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert panel report 3 (epr-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007 Nov;120(5Suppl):S94–138. Erratum in: J Allergy Clin Immunol. 2008 Jun;121(6):1330.
   PubMedGoogle Scholar
• Xolair (Omalizumab) [package insert]. San Francisco, CA: Genentech; 2017.
   Google Scholar
• Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):525–36.e1.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014 Jan;13(1):CD003559.
   Google Scholar
• Pepper AN, Renz H, Casale TB, et al. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. 2017;5(4): 909–916. Jul - Aug.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804–811.
   PubMed Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy.  2018 Feb;73(2):490–497.
   PubMed Web of Science ®Google Scholar
• Cox L, Platts-Mills TA, Finegold I, et al. American academy of allergy, asthma & immunology.; American college of allergy, asthma and immunology. American academy of allergy, asthma & immunology/American college of allergy, asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007 Dec;120(6):1373–1377.
   PubMed Web of Science ®Google Scholar
• Miller CW, Krishnaswamy N, Johnston C, et al. Severe asthma and the omalizumab option. Clin Mol Allergy. 2008 May;20(6):4.
   Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012 Apr;129(4):983–9.e6.
   PubMed Web of Science ®Google Scholar
• Patel TR, Sur S. IgE and eosinophils as therapeutic targets in asthma. Curr Opin Allergy Clin Immunol. 2017;17:42–49.
   PubMed Web of Science ®Google Scholar
• Domingo C, Overlapping. Effects of new monoclonal antibodies for severe asthma. Drugs. 2017 Oct;77(16):1769–1787.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Gallelli L, et al. Dupilumab for the treatment of asthma. Expert Opin Biol Ther. 2017 Dec;17(12):1565–1572. Epub 2017 Oct 8.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. N Engl J Med. 2013 Sep 26;369(13):1276.
   PubMedGoogle Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Jul 2; 388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma. Cision PR Newswire. New York City: PR Newswire, 2017. Available at: https://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-uncontrolled-persistent-asthma-300516839.html. 16 December 2017.
   Google Scholar
• Fasenra (Benralizumab) [package insert]. (Wilmington, DE): Astra Zeneca; 2017.
   Google Scholar
• Dupixent (Dupilumab) [package insert]. (Tarrytown, NY): Regeneron; 2017.
   Google Scholar